- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum | 1 | GlobeNewswire (USA) | ||
| Mo | Artiva Biotherapeutics treibt Phase-III-Studie für Rheuma-Therapie voran | 2 | Investing.com Deutsch | ||
| 11.09. | Artiva Biotherapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 11.09. | Artiva Biotherapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| ARTIVA BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 08.09. | Artiva initiates phase 3 trial for refractory arthritis therapy | 3 | Investing.com | ||
| 08.09. | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Provides Update on Planned AlloNK Data Disclosures and Development Milestones for the Remainder of 2026 | 173 | GlobeNewswire (Europe) | Updated clinical data expected in the second half of 2026 from at least 20 patients with refractory rheumatoid arthritis (RA) treated with AlloNK and rituximab in the ongoing company-sponsored Phase... ► Artikel lesen | |
| 07.08. | Artiva BioTherapeutics GAAP EPS of -$0.63 | 1 | Seeking Alpha | ||
| 22.07. | Artiva Biotherapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 17.07. | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 08.06. | Artiva presents rheumatoid arthritis therapy data at EULAR | 4 | Investing.com | ||
| 08.06. | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Highlights AlloNK Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today | 2 | GlobeNewswire (USA) | ||
| 26.05. | Cantor Fitzgerald reiterates Artiva Biotherapeutics stock rating | 2 | Investing.com | ||
| 26.05. | Cantor Fitzgerald bekräftigt "Overweight"-Rating für Artiva Biotherapeutics | 5 | Investing.com Deutsch | ||
| 19.05. | Artiva to present AlloNK therapy data at EULAR congress | 1 | Investing.com | ||
| 19.05. | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Announces Multiple AlloNK Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in ... | 5 | GlobeNewswire (USA) | ||
| 19.05. | Artiva Biotherapeutics appoints Diego Miralles as president, R&D head | 1 | Investing.com | ||
| 19.05. | Artiva Biotherapeutics beruft Diego Miralles zum President und Leiter für Forschung und Entwicklung | 1 | Investing.com Deutsch | ||
| 19.05. | Artiva Biotherapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.05. | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development | 846 | GlobeNewswire (Europe) | Veteran biotechnology executive with more than 20 years of leadership experience spanning research, clinical development, commercialization and company building Proven track record advancing multiple... ► Artikel lesen | |
| 11.05. | H.C. Wainwright raises Artiva Biotherapeutics price target to $35 | 2 | Investing.com |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 83,80 | -2,61 % | Biontech-Großaktionär rechnet mit baldiger Vorstands-Neubesetzung | Mainz - Einer der Großaktionäre und Mitgründer von Biontech, Thomas Strüngmann, rechnet mit einer baldigen Neubesetzung im Vorstand des Mainzer Biotechunternehmens."Die Berufung eines neuen Medizinvorstands... ► Artikel lesen | |
| AMGEN | 335,15 | +1,30 % | Amgen-Aktie: Kann man jetzt schon ein Schnäppchen machen? | Es ist eine bislang miserable Handelswoche für die Amgen-Aktie. Seit Wochenbeginn ging es mit dem Kurs des US-Biopharmariesen um über -13% bergab. Was zieht Amgen dieser Tage in den Kurskeller und können... ► Artikel lesen | |
| NOVAVAX | 8,670 | -0,46 % | Novavax: Langfristige Aussichten im Spannungsfeld von Innovation und Konkurrenz | ||
| BIOGEN | 189,04 | -0,87 % | Biogen Inc.: Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN | EMPAVELI-treated adolescents achieved a 75% relative reduction in proteinuria within 6 months versus placebo EMPAVELI is the only approved treatment for adolescents with C3G and primary IC-MPGN, based... ► Artikel lesen | |
| CLINUVEL | 5,022 | +0,08 % | CLINUVEL PHARMACEUTICALS LIMITED: CLINUVEL date of Annual General Meeting | ||
| VIKING THERAPEUTICS | 25,100 | -1,95 % | Wall Street Sees a Huge Rebound for Viking Therapeutics. Here's Why Analysts Are So Optimistic. | ||
| INTELLIA THERAPEUTICS | 10,360 | -3,00 % | Cathie Wood's ARK sells Twist Bioscience stock, buys more Intellia | ||
| TEMPUS AI | 67,70 | -3,23 % | Tempus AI stock is soaring: does it have more upside to go? | ||
| BIOCRYST PHARMACEUTICALS | 7,490 | -1,00 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Approval of ORLADEYO for Pediatric HAE Patients in Japan | - Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc.... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 56,08 | -1,09 % | BioMarin Pharmaceutical Inc.: BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors | SAN RAFAEL, Calif., Sept. 14, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the company has appointed Robert Plenge, M.D., Ph.D.... ► Artikel lesen | |
| EXELIXIS | 50,76 | -0,37 % | Citizens reiterates Exelixis stock rating on FDA review extension | ||
| SAREPTA THERAPEUTICS | 17,280 | -4,00 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| CARDIOL THERAPEUTICS | 1,664 | 0,00 % | Cardiol Therapeutics Inc: Cardiol receives $7M (U.S.) from warrant exercise | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,209 | +0,21 % | PacBio Appoints Mark Van Oene as President and Chief Executive Officer | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) ("PacBio"), a leading developer of high-quality, highly accurate sequencing solutions,... ► Artikel lesen | |
| VAXART | 0,600 | 0,00 % | Vaxart, Inc. - 8-K, Current Report |
ARTIVA BIOTHERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,170 (+2,02 %) liegt der Kurs bei 8,600 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARTIVA BIOTHERAPEUTICS INC finden Sie auf Wallstreet Online.